Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
复制标题
来自哥伦比亚和西班牙的 HPV-16 DNA 阳性浸润性宫颈癌和宫颈上皮内瘤变 III 级患者和对照患者对人乳头瘤病毒 16 型 (HPV-16) 病毒样颗粒的血清学反应。
DOI：
10.1093/infdis/172.1.19
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Schiller,JT
中科院分区：
文献类型：
--
作者：
Nonnenmacher,B;Hubbert,NL;Kirnbauer,R;Shah,KV;Muñoz,N;Bosch,FX;deSanjosé,S;Viscidi,R;Lowy,DR;Schiller,JT
一种基于人乳头瘤病毒（HPV）16型病毒样颗粒的ELISA用于评估300名参与哥伦比亚和西班牙宫颈癌病例对照研究的妇女的抗病毒免疫应答。在哥伦比亚和西班牙，分别有51%和59%的HPV-16 DNA阳性浸润性宫颈癌妇女和81%和73%的HPV-16 DNA阳性宫颈上皮内瘤变III级（CIN III）妇女的血清中检测到病毒体IgG抗体。在哥伦比亚和西班牙分别有22%和3%的癌症对照（P<0.001）和43%和10%的CIN III对照（P= 0.010）中检测到衣壳抗体。由于哥伦比亚的宫颈癌发病率高出8倍，这些结果表明ELISA阳性与癌症风险之间存在关联。衣壳抗体反应与同一妇女对HPV-16 E6和E7癌蛋白的体液反应无关。
A human papillomavirus (HPV) type 16 virus-like particle-based ELISA was used to assess antivirion immune responses in 300 women participating in cervical cancer case-control studies in Colombia and Spain. Virion IgG antibodies were detected in the sera of 51% and 59% of women with HPV-16 DNA-positive invasive cervical cancer and 81% and 73% of women with HPV-16 DNA-positive cervical intraepithelial neoplasia grade III (CIN III) in Colombia and Spain, respectively. Capsid antibodies were detected in 22% and 3% of cancer controls (P< .001) and in 43% and 10% of CIN III controls (P= .010) from Colombia and Spain, respectively. Since Colombia has an 8-fold higher incidence of cervical cancer, these results demonstrate an association between ELISA positivity and cancer risk. Capsid antibody responses did not correlate with humoral responses of the same women to HPV-16 E6 and E7 oncoproteins.